Vytora Health Review

What Vytora Health charges

• NAD+: $249/mo — per month on a month-to-month plan, in the page's own FAQ answer; the same answer gives $200/month on a 3-month plan billed $600 every 3 months, and states the figure includes medication, physician consultation, supplies, shipping and support, with the same price at every dose
• Sermorelin: $249/mo — per month on a month-to-month plan, from the page's own FAQ answer, which also gives $186/month on a 3-month plan billed $559 every 3 months. ⛔ The price block at the top of the SAME page prints "$199 / month · Billed monthly" — an unreconciled third figure; the more expensive month-to-month reading is the one recorded

The disclosure shape almost nobody else here produces

Each product page answers a cost question in its own words. The answer names the month-to-month rate, names the rate on a three-month plan, and states the amount charged every three months to produce it. All three numbers are in one sentence.

The same answer says what the figure covers: medication, physician consultation, supplies, shipping and ongoing support. It also says the price is the same at every dose, so titrating up does not move the bill.

That is the shape a reader needs to compare a prepayment against a monthly charge, and it is rare on this roster. A per-month figure derived from a prepaid block is only honest when the block is printed beside it, and here it is.

The pages also say plainly that this is a recurring subscription. A seller stating the billing model before the intake is a small thing that saves a reader a surprise.

And then one page contradicts itself

The sermorelin page carries a price block above the fold with a one-month and three-month toggle and a per-month figure marked as billed monthly. Its own cost answer, further down the same page, gives a higher month-to-month figure and a lower three-month figure.

Two of those cannot both be the month-to-month rate. The page offers nothing that reconciles them — no promotional label, no first-month wording, no footnote.

This site records the more expensive month-to-month reading, which is its standing rule when a seller contradicts itself, and names the conflict on the row rather than averaging the two.

The other product page has the same two surfaces and they agree. So the problem is one page, not a design, which makes it likelier to be an unrevised number than a deliberate structure.

Two companies, and two spellings of one of them

The terms separate the roles cleanly. The brand company is described as a technology platform providing marketing and administrative services, explicitly not a medical provider and not a pharmacy. Clinical services are provided through a separate professional practice.

That separation is honest and is more than most sellers here offer. The practice, however, is named with one corporate suffix in the body of the terms and a different one in the footer that appears on every page.

A reader looking the practice up would search two different entities. It is a small inconsistency and it is the kind that a licensing lookup turns into a dead end.

The compounding pharmacies are described as a network of licensed United States facilities and are never named individually.

Coverage, testing, and what is not said

No state list appears anywhere. The terms say only that certain services are available to individuals in certain states, which is a sentence that tells a reader nothing about their own.

Nothing on either product page describes lab work as included at any plan length.

No certificate of analysis, purity report or third-party testing claim appears in the text of any page read here. The footer does carry a certification claim from a pharmacy-standards body, which is a different assurance and is not evidence about a batch.

The pages carry a prescription-required notice and say a licensed provider reviews health history before prescribing. Both product pages sit under headings the seller chose itself, one filed under peptide therapy and one under anti-aging.

How we verified this

• Loaded both product pages and both legal pages with a full browser user-agent, printed the effective URL beside the requested URL on every fetch, and confirmed none redirected.
• Ran a nonsense-path control on the host in the same run and confirmed a not-found response.
• Joined the page's text nodes before matching any price, so a figure split across two elements could not read as an absence.
• Compared the price block and the cost answer on each product page against each other rather than reading only one surface, which is the only reason the sermorelin conflict was found.
• Recorded the more expensive reading of the contradicted figure and named the conflict, rather than choosing the reading that flatters the seller.
• Corrected the research note's placement of the conflicting figure, which had recorded it on the homepage rather than on the product page where it sits.
• Read both legal pages in full for the operating entities, and found the practice named with two different corporate suffixes on the same page.
• Searched the extracted text of every page for certificate, purity and third-party testing language and found none.
• Took the state position from the terms' own sentence rather than inferring coverage from the absence of a list.